keyword
MENU ▼
Read by QxMD icon Read
search

Mirabegron

keyword
https://www.readbyqxmd.com/read/28446460/inhibition-of-cholinergic-neurotransmission-by-%C3%AE-3-adrenoceptors-depends-on-adenosine-release-and-a1-receptors-activation-in-human-and-rat-urinary-bladders
#1
Isabel Silva, Ana Filipa Costa, Sílvia Moreira, Fátima Ferreirinha, Maria Teresa Magalhães-Cardoso, Isabel Calejo, Miguel Silva-Ramos, Paulo Correia-de-Sá
The direct detrusor relaxant effect of β3-adrenoceptor agonists as a primary mechanism to improve overactive bladder symptoms has been questioned. Among other targets, activation of β3-adrenoceptors down-modulate nerve-evoked acetylcholine (ACh) release, but there is insufficient evidence for the presence of these receptors on bladder cholinergic nerve terminals. Our hypothesis is that adenosine formed from the catabolism of cyclic AMP in the detrusor may act as a retrograde messenger via prejunctional A1 receptors to explain inhibition of cholinergic activity by β3-adrenoceptors...
April 26, 2017: American Journal of Physiology. Renal Physiology
https://www.readbyqxmd.com/read/28436145/comparisons-of-the-clinical-outcomes-and-urodynamic-effects-of-mirabegron-versus-tolterodine-treatment-for-female-overactive-bladder-syndrome-a-subgroup-analysis-of-a-controlled-randomised-prospective-study
#2
Sheng-Mou Hsiao, Ting-Chen Chang, Chi-Hau Chen, Wen-Yih Wu, Ho-Hsiung Lin
OBJECTIVES: The impact of mirabegron on clinical outcome and urodynamic parameters may be important for clinical practice. Thus, the aim of this study was to compare the clinical outcomes and urodynamic effects of mirabegron (Betmiga 50 mg) versus tolterodine (Detrusitol ER 4 mg) treatment for women with overactive bladder syndrome (OAB). METHODS: Women with OAB were randomized to receive 12 weeks of mirabegron 50 mg, tolterodine extended-release 4 mg or placebo treatment...
April 23, 2017: Lower Urinary Tract Symptoms
https://www.readbyqxmd.com/read/28434969/translational-science-approach-for-assessment-of-cardiovascular-effects-and-proarrhythmogenic-potential-of-the-beta-3-adrenergic-agonist-mirabegron
#3
Cees Korstanje, Masanori Suzuki, Koichiro Yuno, Shuichi Sato, Masashi Ukai, Marlowe J Schneidkraut, Gan X Yan
INTRODUCTION: Translational assessment of cardiac safety parameters is a challenge in clinical development of beta-3 adrenoceptor agonists. The preclinical tools are presented that were used for assessing human safety for mirabegron. METHODS: Studies were performed on electrical conductance at ion channels responsible for cardiac repolarization (IKr, IKs, Ito, INa, and ICa,L), on QT-interval, subendocardial APD90, Tpeak-end interval, and arrhythmia's in ventricular dog wedge tissue in vitro and on cardiovascular function (BP, HR, and QTc) in conscious dogs...
April 20, 2017: Journal of Pharmacological and Toxicological Methods
https://www.readbyqxmd.com/read/28419650/cardiovascular-safety-in-refractory-incontinent-patients-with-overactive-bladder-receiving-add-on-mirabegron-therapy-to-solifenacin-beside
#4
Marcus J Drake, Scott MacDiarmid, Christopher R Chapple, Adil Esen, Stavros Athanasiou, Javier Cambronero Santos, David Mitcheson, Sender Herschorn, Emad Siddiqui, Moses Huang, Matthias Stoelzel
AIMS/OBJECTIVES: In the BESIDE study, combination therapy (antimuscarinic [solifenacin] and β3 -adrenoceptor agonist [mirabegron]) improved efficacy over solifenacin monotherapy without exacerbating anticholinergic side effects in overactive bladder (OAB) patients; however, a potential synergistic effect on the cardiovascular (CV) system requires investigation. METHODS: OAB patients remaining incontinent despite daily solifenacin 5 mg during 4-week single-blind run-in, were randomised 1:1:1 to double-blind daily combination (solifenacin 5 mg/mirabegron 25 mg, increasing to 50 mg after week 4), solifenacin 5 or 10 mg for 12 weeks...
April 16, 2017: International Journal of Clinical Practice
https://www.readbyqxmd.com/read/28418102/efficacy-and-safety-of-combinations-of-mirabegron-and-solifenacin-compared-with-monotherapy-and-placebo-in-patients-with-overactive-bladder-synergy-study
#5
Sender Herschorn, Christopher R Chapple, Paul Abrams, Salvador Arlandis, David Mitcheson, Kyu-Sung Lee, Arwin Ridder, Matthias Stoelzel, Asha Paireddy, Rob van Maanen, Dudley Robinson
Overactive bladder (OAB) syndrome is characterized by urinary urgency, with or without urgency urinary incontinence, usually accompanied by increased daytime frequency and nocturia, in the absence of urinary tract infection (UTI) or other obvious pathology [1]. Urgency urinary incontinence is present in approximately one-third of cases [2], but is not a prerequisite. However, of all the OAB symptoms, it has the greatest impact on quality of life (QoL) [3, 4], and is associated with significantly lower productivity and higher healthcare resource utilization [5]...
April 18, 2017: BJU International
https://www.readbyqxmd.com/read/28400166/better-persistence-rates-with-mirabegron-questions-raised
#6
EDITORIAL
Alan J Wein
No abstract text is available yet for this article.
April 8, 2017: European Urology
https://www.readbyqxmd.com/read/28394529/-comprehensive-pharmacologic-management-of-overactive-bladder
#7
G G Krivoborodov, E I Tur
Overactive bladder (OAB) is a common and bothersome condition manifested by urgency, frequent urination, significantly impairing patients quality of life. The article presents an overview of the evidence on pharmacotherapy of neurogenic and idiopathic OAB. Selective M3 receptor blockers have been shown to be the medications of choice in treating these patients. Many studies have shown that solifenacin 10 mg is a starting dose for patients with OAB. Mirabegron (Betmiga) is the only 3-adrenergic receptor agonist approved for primary treatment of OAB patients refractory to anticholinergics or have their side effects...
April 2017: Urologii︠a︡
https://www.readbyqxmd.com/read/28371019/adherence-and-persistence-of-mirabegron-and-anticholinergic-therapies-in-patients-with-overactive-bladder-a-real-world-claims-data-analysis
#8
D Sussman, A Yehoshua, J Kowalski, W Lee, J Kish, S Chaudhari, B Murray
BACKGROUND: Adherence and persistence rates of anticholinergic (ACH) therapies have been well described. To date, few studies describe these metrics for mirabegron in patients with overactive bladder. METHODS: This retrospective analysis of MarketScan(®) database assessed adherence and persistence of patients receiving either mirabegron or ACH. Study eligibility required an index date (first prescription filled) between July 2012 and June 2013 with 12 months of continuous enrolment preindex date and 12 months of follow-up...
March 2017: International Journal of Clinical Practice
https://www.readbyqxmd.com/read/28370541/a-prospective-study-of-elderly-initiating-mirabegron-versus-antimuscarinics-patient-reported-outcomes-from-the-overactive-bladder-satisfaction-scales-and-other-instruments
#9
Suvapun Bunniran, Cralen Davis, Rita Kristy, Daniel Ng, Carol R Schermer, Claudia Uribe, Brandon T Suehs
AIMS: To understand differences in patient reported outcomes (PRO) between patients initiating mirabegron or an antimuscarinic using a validated PRO instrument, OAB-Satisfaction (OAB-S). METHODS: This prospective observational study used real-time prescription claims from Humana to identify Medicare patients initiating mirabegron or an antimuscarinic to participate in a series of three phone surveys over ninety days. RESULTS: A total of 1897 mirabegron and 2444 randomly selected antimuscarinic initiators were identified; 174 mirabegron and 193 antimuscarinic initiators completed all three surveys...
March 31, 2017: Neurourology and Urodynamics
https://www.readbyqxmd.com/read/28361520/on-the-site-and-mechanism-of-action-of-%C3%AE-3-adrenoceptor-agonists-in-the-bladder
#10
REVIEW
Karl Erik Andersson
The clinical success of mirabegron as the first β3-adrenoceptor (AR) agonist for treatment of the overactive bladder (OAB) syndrome, has resulted in substantial interest in its site and mechanism of action. Even if the adrenergic innervation of the bladder and urethra has been well studied, the location(s) of β3-ARs in different structures within the bladder wall and urethra, and the mode(s) of action of β3-AR stimulation have still not been established. The recent demonstration of β3-ARs on cholinergic nerve terminals with no immunoreactivity in urothelium or detrusor smooth muscle, is not in agreement with previous morphological studies, and functional data strongly suggest that β3-ARs can be found these structures...
March 24, 2017: International Neurourology Journal
https://www.readbyqxmd.com/read/28322904/adding-mirabegron-to-solifenacin-to-treat-overactive-bladder-has-little-impact-on-post-void-residual-volume-or-urinary-retention-risk
#11
M J Drake, S MacDiarmid, S Al-Shukri, J Barkin, A Fianu-Jonasson, S Herschorn, M Huang, M Stoelzel, E Siddiqui
No abstract text is available yet for this article.
March 16, 2017: Urology
https://www.readbyqxmd.com/read/28293939/current-evidence-and-emerging-drug-therapies-for-overactive-bladder
#12
Matthew Izett, Martino Zacche, Ganesh Thiagamoorthy, Dudley Robinson, Linda Cardozo
Overactive bladder is a common symptom complex with health related quality of life impacts on the individual as well as utilizing health resources. Antimuscarinic therapy has been the mainstay of treatment and is well supported within the literature and guidelines. However, compliance is poor due to lack of efficacy and adverse events leading to the development of novel therapies. Mirabegron, the B3-adrenoreceptor agonist has emerged as an evidence-based alternative first or second line therapy. Two decades after its first clinical application for overactive bladder, intravesical botulinum toxin is now an important part of any clinician's armamentarium for refractory cases...
June 2017: Minerva Ginecologica
https://www.readbyqxmd.com/read/28286993/clinical-and-economic-impact-of-mirabegron-compared-with-antimuscarinics-for-the-treatment-of-overactive-bladder-in-canada
#13
Zalmai Hakimi, Jameel Nazir, Charles McCrea, Malin Berling, Francis Fatoye, Barbara Ramos, Adrian Wagg
BACKGROUND: The β3-adrenoceptor agonist, mirabegron, and antimuscarinic agents provide similar efficacy for the treatment of overactive bladder (OAB), but mirabegron appears to be associated with better persistence, perhaps due to an absence of anticholinergic side-effects. This study estimated the expected costs associated with the management of OAB in Canada from a societal perspective by utilizing real-world evidence. METHODS: An economic model with monthly cycles and a 1-year time horizon was developed to depict a treatment pathway for a hypothetical cohort of 100 patients with OAB...
March 12, 2017: Journal of Medical Economics
https://www.readbyqxmd.com/read/28273884/2d-qsar-and-3d-qsar-comsia-studies-on-a-series-of-r-2-2-1h-indol-2-yl-ethyl-amino-1-phenylethan-1-ol-with-human-%C3%AE-%C3%A2-adrenergic-activity
#14
Gastón Apablaza, Luisa Montoya, Cesar Morales-Verdejo, Marco Mellado, Mauricio Cuellar, Carlos F Lagos, Jorge Soto-Delgado, Hery Chung, Carlos David Pessoa-Mahana, Jaime Mella
The β₃ adrenergic receptor is raising as an important drug target for the treatment of pathologies such as diabetes, obesity, depression, and cardiac diseases among others. Several attempts to obtain selective and high affinity ligands have been made. Currently, Mirabegron is the only available drug on the market that targets this receptor approved for the treatment of overactive bladder. However, the FDA (Food and Drug Administration) in USA and the MHRA (Medicines and Healthcare products Regulatory Agency) in UK have made reports of potentially life-threatening side effects associated with the administration of Mirabegron, casting doubts on the continuity of this compound...
March 5, 2017: Molecules: a Journal of Synthetic Chemistry and Natural Product Chemistry
https://www.readbyqxmd.com/read/28255232/profile-of-mirabegron-in-the-treatment-of-overactive-bladder-place-in-therapy
#15
REVIEW
Ala'a Sharaf, Hashim Hashim
Mirabegron is a relatively new drug introduced to treat overactive bladder syndrome. It can be used either on its own or as part of a combination. This drug has been extensively studied, with a good number of Phase II and Phase III trials showing promising outcomes. These studies show that mirabegron is an effective, well-tolerated drug, which could have some adverse effects of concern. In this review, we look at the trials on mirabegron, as well as its pharmacokinetics, mechanism of action, and side effects as documented in the literature...
2017: Drug Design, Development and Therapy
https://www.readbyqxmd.com/read/28252310/-degree-of-satisfaction-of-patients-continuing-overactive-bladder-treatment-with-mirabegron
#16
K Švabík, J Mašata, J Krhut, R Zachoval, T Hanuš, M Halaška, L Horčička, L Krofta, M Hanáková, A Martan
OBJECTIVE: Overactive bladder syndrome is chronic disease with high prevalence rate (9-42%). This syndrome requires long term therapy, but the treatment persistence is after 3 months over all 26% with further decline in one-year period as low as 18.5%. Main reasons for stopping the treatment are low efficacy, the medication didnt work as expected and side effects. How much satisfied are patients with mirabegron persisting on its treatment? To answer this question, we provided secondary analysis of multicentre follow-up study of patients on mirabegron...
2017: Ceská Gynekologie
https://www.readbyqxmd.com/read/28228331/-efficacy-and-safety-of-available-therapies-in-the-management-of-idiopathic-overactive-bladder-a-systematic-review-of-the-literature
#17
J Moyson, F Legrand, M Vanden Bossche, T Quackels, T Roumeguère
OBJECTIVE: Study the efficacy and adverse events of different pharmacological lines in the treatment of idiopathic overactive bladder (iOAB). METHODS: PubMed research on meta-analyses and randomized controlled trials (RCT) focused on the efficacy and adverse effects of anticholinergics, botulinum toxin and mirabegron since 2005. RESULTS: Ten meta-analyses of anticholinergics were selected; 16 randomized controlled trials (ERC) comparing botulinum toxin A to either anticholinergic or placebo and 10 ERC studying mirabegron...
February 19, 2017: Progrès en Urologie
https://www.readbyqxmd.com/read/28220521/indirect-treatment-comparison-itc-of-medical-therapies-for-an-overactive-bladder
#18
Aneta Obloza, Joshua Kirby, Derrick Yates, Philip Toozs-Hobson
BACKGROUND: Overactive bladder syndrome (OAB) is a chronic and prevalent condition which has a negative impact on Quality of Life. The National Institute of Clinical Excellence issued two documents which give slightly varying algorithms of pharmacotherapy for OAB, offering mirabegron as a possible treatment in certain circumstances. In the absence of trials involving a direct comparison of therapies, an indirect comparison can provide useful information on the difference in treatment effects between competing interventions...
February 21, 2017: Neurourology and Urodynamics
https://www.readbyqxmd.com/read/28208559/re-mirabegron-causes-relaxation-of-human-and-rat-corpus-cavernosum-could-it-be-a-potential-therapy-for-erectile-dysfunction
#19
Allen D Seftel
No abstract text is available yet for this article.
March 2017: Journal of Urology
https://www.readbyqxmd.com/read/28208543/re-efficacy-and-safety-of-mirabegron-add-on-therapy-to-solifenacin-in-incontinent-overactive-bladder-patients-with-an-inadequate-response-to-initial-4-week-solifenacin-monotherapy-a-randomised-double-blind-multicentre-phase-3b-study-beside
#20
keyword
keyword
7718
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"